Date: 24 February 2023

Dear Healthcare Professional,

Alternative supply arrangement under Section 19A of the *Therapeutic Goods Act 1989*.

The Australian registered medicine SUXAMETHONIUM JUNO 100mg/2mL injection ampoule AUST R 320687 sponsored by Juno Pharmaceuticals Pty Ltd is unavailable due to manufacturing issues. This is a sole supply product. To avoid any shortages Juno has been able to arrange supply of an alternative product **Suxamethonium Chloride Solution for Injection 100mg/2mL (Mercury Pharma)**, on a temporary basis. This product is NOT registered in Australia and supply is authorised under an approval granted by the Therapeutic Goods Administration (TGA) under section 19A of the *Therapeutic Goods Act 1989* until 31 August 2023 for the following indication:

- *For the production of skeletal muscle relaxation in anaesthesia. Suited for procedures requiring only brief relaxation such as endotracheal intubation, endoscopic examinations, orthopaedic manipulations, short surgical procedures and electro-convulsive therapy.*

Suxamethonium Chloride Solution for Injection 100mg/2mL (Mercury Pharma) is registered and marketed in the United Kingdom by Mercury Pharmaceuticals Limited.

The S19A approved UK product is identical in active ingredient and strength to the Australian registered product. A comparison table of formulation differences is given below:

Product	**SUXAMETHONIUM JUNO 100mg/2mL injection ampoule AUST R 320687**	**Suxamethonium Chloride Solution for Injection 100mg/2mL (Mercury Pharma)**
Active ingredient	Suxamethonium chloride dihydrate 100 mg per 2mL ampoule	Suxamethonium chloride dihydrate 100 mg per 2mL ampoule
Excipients	Water for injection Hydrochloric acid for pH adjustment	Sodium acetate BP Water for injections BP

Please refer to the Australian Product Information for Suxamethonium Juno 100mg/2mL injection ampoule AUST R 320687 (available at https://www.ebs.tga.gov.au) when prescribing and administering **Suxamethonium Chloride Solution for Injection 100mg/2mL (Mercury Pharma)**.

Adverse Event Reporting

Reporting any suspected adverse event is important for the continued monitoring of the safety of all medicines. Any adverse events which are experienced with Suxamethonium Chloride Solution for Injection 100mg/2mL (Mercury Pharma) should be reported by healthcare professionals and patients to **Juno Pharmaceuticals Pty Ltd** on 1800 620 076 or by email medical-enquiries@junopharm.com.au. Alternatively, this information can be reported to the TGA via https://www.tga.gov.au/reporting-problems.

Please forward this information to relevant staff members in your organisation.

For further information, please contact Juno Pharmaceuticals Pty Ltd on 03 8888 1288 or email info@junopharm.com.au.

Yours sincerely

Senan Kiely
Regulatory Affairs Manager
Phone: 0423 826 459
Fax: 03 8888 1299
Email: senan.kiely@junopharm.com.au